S
Spero Therapeutics Inc (SPRO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$0.95
-0.05 (-5.35%)
Market Cap: $58.26M
Last updated: Nov 17, 2026 at 11:05 AM ET
Spero Therapeutics Inc (SPRO) P/E Ratio & Valuation History
Spero Therapeutics (SPRO) trades at 11.1x trailing earnings and 1.3x sales. Its P/S of 1.3x is below its 5-year median of 1.6x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | 11.1x |
| Forward P/E | N/A |
| Price to sales | 1.3x |
| Price to book | 70.6x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/S is 77.6% below 5.8x and its P/B is 3261.9% above 2.1x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.3x | 1.6x | 5.8x |
| P/B | 70.6x | 1.4x | 2.1x |
Valuation History
Over the 9 year ends shown, its P/S ranged from 0.8x in 2023 to 45.9x in 2020.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $2.33 | 19.3x | 2.0x | 2.3x |
| 2024 | $1.03 | N/A | 1.2x | 1.2x |
| 2023 | $1.47 | 2.8x | 0.8x | 0.7x |
| 2022 | $1.73 | N/A | 1.5x | 1.1x |
| 2021 | $16.01 | N/A | 26.6x | 5.8x |
| 2020 | $19.39 | N/A | 45.9x | 4.0x |
| 2019 | $9.62 | N/A | 9.4x | 2.5x |
| 2018 | $6.15 | N/A | 25.1x | 0.9x |
| 2017 | $11.75 | N/A | 6.1x | 1.9x |
Frequently Asked Questions About SPRO
What is SPRO's price to sales ratio?
Spero Therapeutics has a price to sales ratio of 1.3x.
SPRO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts